Osteal Therapeutics Receives Series D Funding for Commercial Launch
David Thompson, Chairman & CEO, Osteal Therapeutics Osteal Therapeutics is tackling periprosthetic joint infection (PJI) with a drug/device combination device. PJI is a condition in which bacteria deposits on artificial joins creating "biofilms". Within these films, bacteria are able to protect themselves from antibiotics, making this a serious condition. Osteal's product, VT-X7, directly delivers antibiotics to the affected area for seven days, thus avoiding systemic toxicology from traditional treatments. Currently, in phase two trials, VT-X7 is showing promising results. 
Osteal Therapeutics Receives Series D Funding for Commercial Launch
